Vaxart (VXRT) 10-Q 6 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 05, 2020
Document Information [Line Items]
Entity Registrant Name	Vaxart, Inc.
Entity Central Index Key	0000072444
Trading Symbol	vxrt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		109,201,829
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.10 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 44,388	$ 13,526
Accounts receivable	227	3,619
Prepaid expenses and other current assets	1,111	453
Total current assets	45,726	17,598
Property and equipment, net	345	210
Right-of-use assets, net	1,755	1,990
Intangible assets, net	16,227	17,093
Other long-term assets	137	141
Total assets	64,190	37,032
Current liabilities:
Accounts payable	1,166	852
Current portion of operating lease liability	804	841
Liability related to sale of future royalties, current portion	3,150	2,916
Other accrued liabilities	6,378	4,565
Total current liabilities	11,498	9,174
Operating lease liability, net of current portion	1,120	1,472
Liability related to sale of future royalties, net of current portion	11,319	13,416
Other long-term liabilities	18	18
Total liabilities	23,955	24,080
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2020 and December 31, 2019
Common stock: $0.0001 par value; 150,000,000 shares authorized; 96,140,661 and 48,254,994 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	10	5
Additional paid-in capital	167,160	129,608
Accumulated deficit	(126,935)	(116,661)
Total stockholders’ equity	40,235	12,952
Total liabilities and stockholders’ equity	$ 64,190	$ 37,032

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	96,140,661	48,254,994
Common stock, shares outstanding (in shares)	96,140,661	48,254,994

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Revenue	$ 523	$ 85	$ 3,425	$ 5,492
Operating expenses:
Research and development	5,114	3,707	6,656	7,536
General and administrative	3,896	1,375	5,886	3,401
Restructuring costs	39		103
Total operating expenses	9,049	5,082	12,645	10,937
Operating loss	(8,526)	(4,997)	(9,220)	(5,445)
Other income and (expenses):
Interest income	23	34	64	39
Interest expense		(97)		(204)
Non-cash interest expense related to sale of future royalties	(446)	(516)	(937)	(1,060)
Foreign exchange loss, net	(2)	(48)	(2)	(43)
Total other income and (expenses)	(425)	(627)	(875)	(1,268)
Net loss before income taxes	(8,951)	(5,624)	(10,095)	(6,713)
Provision for income taxes	26	13	179	263
Net loss	$ (8,977)	$ (5,637)	$ (10,274)	$ (6,976)
Net loss per share - basic and diluted (in dollars per share)	$ (0.12)	$ (0.39)	$ (0.15)	$ (0.64)
Shares used to compute net loss per share - basic and diluted (in shares)	74,675,131	14,597,446	67,676,138	10,969,473
Customer Service Contracts [Member]
Revenue:
Revenue	$ 92		$ 191
Royalty [Member]
Revenue:
Revenue	193	69	2,962	3,728
Non Cash Royalty Revenue [Member]
Revenue:
Revenue	$ 238	$ 16	$ 272	$ 1,764

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Underwriters' Designees [Member]Common Stock [Member]	Underwriters' Designees [Member]Additional Paid-in Capital [Member]	Underwriters' Designees [Member]Retained Earnings [Member]	Underwriters' Designees [Member]	Placement Agents' Designees [Member]Common Stock [Member]	Placement Agents' Designees [Member]Additional Paid-in Capital [Member]	Placement Agents' Designees [Member]Retained Earnings [Member]	Placement Agents' Designees [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2018													7,141,189,000				7,141,189
Balances at Dec. 31, 2018											$ (27)	$ (27)	$ 1	$ 109,226	$ (98,016)	$ 11,211	$ 1	$ 109,226	$ (97,989)	$ 11,238
Issuance of common stock upon exercise of common stock warrants																	1	651		$ 652
Issuance of common stock upon exercise of stock options (in shares)																				0
Stock-based compensation																		344		$ 344
Net loss																			(6,976)	(6,976)
Issuance of common stock and common stock warrants, net of offering costs (in shares)																	925,455
Issuance of common stock and common stock warrants, net of offering costs																		7,741		7,741
Issuance of common stock warrants to placement agents’ designees		$ 333		$ 333		$ 100		$ 100
Issuance of common stock upon exercise of pre-funded warrants (in shares)																	6,519,091
Issuance of common stock, net of offering costs (in shares)																	1,200,000
Issuance of common stock, net of offering costs																		2,440		2,440
Balances (in shares) at Jun. 30, 2019																	15,785,735
Balances at Jun. 30, 2019																	$ 2	120,835	(104,992)	15,845
Balances (in shares) at Mar. 31, 2019																	8,341,189
Balances at Mar. 31, 2019																	$ 1	111,930	(99,355)	12,576
Issuance of common stock upon exercise of common stock warrants																	1	651		652
Stock-based compensation																		180		180
Net loss																			(5,637)	(5,637)
Issuance of common stock and common stock warrants, net of offering costs (in shares)																	925,455
Issuance of common stock and common stock warrants, net of offering costs																		7,741		7,741
Issuance of common stock warrants to placement agents’ designees		$ 333		$ 333
Issuance of common stock upon exercise of pre-funded warrants (in shares)																	6,519,091
Balances (in shares) at Jun. 30, 2019																	15,785,735
Balances at Jun. 30, 2019																	$ 2	120,835	(104,992)	15,845
Balances (in shares) at Dec. 31, 2019																	48,254,994
Balances at Dec. 31, 2019																	$ 5	129,608	(116,661)	12,952
Issuance of common stock upon exercise of common stock warrants (in shares)																	43,707,286
Issuance of common stock upon exercise of common stock warrants																	$ 5	24,653		$ 24,658
Issuance of common stock upon exercise of stock options (in shares)																	178,381			178,381
Issuance of common stock upon exercise of stock options																		116		$ 116
Disgorgement of short-swing profits, net of costs																		652		652
Stock-based compensation																		2,956		2,956
Net loss																			(10,274)	(10,274)
Issuance of common stock and common stock warrants, net of offering costs (in shares)																	4,000,000
Issuance of common stock and common stock warrants, net of offering costs																		8,722		8,722
Issuance of common stock warrants to placement agents’ designees						$ 453		$ 453
Balances (in shares) at Jun. 30, 2020																	96,140,661
Balances at Jun. 30, 2020																	$ 10	167,160	(126,935)	40,235
Balances (in shares) at Mar. 31, 2020																	72,004,720
Balances at Mar. 31, 2020																	$ 7	149,244	(117,958)	31,293
Issuance of common stock upon exercise of common stock warrants (in shares)																	23,981,166
Issuance of common stock upon exercise of common stock warrants																	$ 3	14,306		14,309
Issuance of common stock upon exercise of stock options (in shares)																	154,775
Issuance of common stock upon exercise of stock options																		98		98
Disgorgement of short-swing profits, net of costs																		652		652
Stock-based compensation																		2,860		2,860
Net loss																			(8,977)	(8,977)
Balances (in shares) at Jun. 30, 2020																	96,140,661
Balances at Jun. 30, 2020																	$ 10	$ 167,160	$ (126,935)	$ 40,235

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Offering costs from issuance of common stock and warrants	$ 1,579	$ 1,278	$ 1,579
Offering costs			$ 560

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (10,274,000)	$ (6,976,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,193,000	2,097,000
Stock-based compensation	2,956,000	344,000
Non-cash interest expense		64,000
Non-cash interest expense related to sale of future royalties	937,000	1,060,000
Non-cash revenue related to sale of future royalties	(2,800,000)	(3,132,000)
Change in operating assets and liabilities:
Accounts receivable	3,392,000	1,761,000
Prepaid expenses and other assets	(657,000)	530,000
Accounts payable	148,000	(347,000)
Other accrued liabilities	1,376,000	(371,000)
Net cash used in operating activities	(3,729,000)	(4,970,000)
Cash flows from investing activities:
Purchase of property and equipment	(13,000)	(711,000)
Proceeds from sale of equipment	3,000
Net cash used in investing activities	(10,000)	(711,000)
Cash flows from financing activities:
Net proceeds from issuance of securities in registered direct offering	9,175,000	2,540,000
Net proceeds from issuance of common stock, pre-funded warrants and common warrants in April 2019 underwritten offering		8,074,000
Proceeds from issuance of common stock upon exercise of pre-funded warrants		652,000
Proceeds from issuance of common stock upon exercise of common stock warrants	24,658,000
Proceeds from issuance of common stock upon exercise of stock options	116,000
Disgorgement of short-swing profits, net of costs	652,000
Repayment of principal on secured promissory note payable to Oxford Finance		(833,000)
Net cash provided by financing activities	34,601,000	10,433,000
Net increase in cash and cash equivalents	30,862,000	4,752,000
Cash, cash equivalents and restricted cash at beginning of the period	13,526,000	11,506,000
Cash, cash equivalents and restricted cash at end of the period	44,388,000	16,258,000
Supplemental disclosure of cash flow information:
Interest paid		136,000
Supplemental disclosure of non-cash financing activity:
Issuance of warrants to placement agent’s representatives	453,000	100,000
Issuance of warrants to underwriters’ designees		333,000
Acquisition of property and equipment included in accounts payable	$ 170,000	$ 47,000

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	, INC. AND SUBSIDIARIES Notes to the Condensed Consolidated Financial Statements (Unaudited) NOTE 1. Organization and Basis of Presentation General Vaxart Biosciences, Inc. was originally incorporated in California in March 2004, July 2007, On February 13, 2018, 0.22148 On March 2, 2020, “March 2020 4,000,000 2,000,000 one $2.50, five $10.0 $9.2 $775,000. 280,000 March 2020 one $3.125 five March 2020 $453,000 10 On June 8, 2020, $0.10 $0.0001 100,000,000 150,000,000. The Company's principal operations are based in South San Francisco, California, and it operates in one

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation December 31, 2019, 10 March 19, 2020 ( no 2 not Basis of Consolidation Use of Estimates Concentration of Credit Risk not The primary focus of the Company's investment strategy is to preserve capital and meet liquidity requirements. The Company's investment policy addresses the level of credit exposure by limiting the concentration in any one no Reclassification $40,000 $88,000 three six June 30, 2019, no Recent Accounting Pronouncements The Company believes that the impact of accounting standards updates recently issued that are not not

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3 . Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three The three Level 1 Level 2 not Level 3 no The Company's money market funds are classified within Level 1 no June 30, 2020. $15,000 December 31, 2019. no six June 30, 2020 2019.

Note 4 - Balance Sheet Componen

Note 4 - Balance Sheet Components	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	NOTE 4 . Balance Sheet Components (a) Cash and Cash Equivalents Cash and cash equivalents comprises the following: June 30, 2020 December 31, 2019 (in thousands) Cash at banks $ 44,388 $ 13,511 Money market funds — 15 Total cash and cash equivalents $ 44,388 $ 13,526 (b) Accounts Receivable Accounts receivable comprises the following: June 30, 2020 December 31, 2019 (in thousands) Royalties receivable $ 227 $ 3,438 Customer service contracts - billed — 181 Accounts receivable $ 227 $ 3,619 The Company has provided no June 30, 2020 December 31, 2019. (c) Property and Equipment, Net Property and equipment, net consists of the following: June 30, 2020 December 31, 2019 (in thousands) Laboratory equipment $ 706 $ 537 Office and computer equipment 142 132 Total property and equipment 848 669 Less: accumulated depreciation (503 ) (459 ) Property and equipment, net $ 345 $ 210 Depreciation expense was $25,000 $125,000 three June 30, 2020 2019 $44,000 $255,000 six June 30, 2020 2019 no six June 30, 2020 2019 (d) Right-of-Use Assets , Net Right-of-use assets, net consists of the following: June 30, 2020 December 31, 2019 (in thousands) Facilities $ 1,751 $ 1,985 Office equipment 4 5 Right-of-use assets, net $ 1,755 $ 1,990 (e) Intangible Assets, Net Intangible assets comprise developed technology and intellectual property. Intangible assets are carried at cost less accumulated amortization. Amortization is computed using the straight-line method over useful lives ranging from 1.3 11.75 20 As of June 30, 2020 9.4 7.5 June 30, 2020 December 31, 2019 (in thousands) Purchased technology $ 22,100 $ 22,100 Intellectual property 80 80 Total cost 22,180 22,180 Less: accumulated amortization (5,953 ) (5,087 ) Intangible assets, net $ 16,227 $ 17,093 Total amortization expense for the three June 30, 2020 2019 $433,000 $675,000, six June 30, 2020 2019 $866,000 $1,454,000, As of June 30, 2020 Year Ending December 31, Amount 2020 (six months remaining) $ 866 2021 1,732 2022 1,731 2023 1,732 2024 1,732 Thereafter 8,434 Total $ 16,227 (f) Other Accrued Liabilities Other accrued liabilities consist of the following: June 30, 2020 December 31, 2019 (in thousands) Accrued compensation $ 1,009 $ 903 Accrued clinical and manufacturing expenses 4,937 3,228 Accrued professional and consulting services 49 2 Reserve for return of royalties — 178 Other liabilities, current portion 383 254 Total $ 6,378 $ 4,565

Note 5 - Revenue

Note 5 - Revenue	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Revenue [Text Block]	NOTE 5 . Revenue Service Contracts with Customers Contract Balances. June 30, 2020 December 31, 2019, nil $181,000, June 30, 2020 December 31, 2019, $212,000 $21,000, Remaining Performance Obligations. June 30, 2020 December 31, 2019, no $20,000 $211,000, not 100% three not not Royalty Agreements Aviragen entered into a royalty-generating research and license agreement with GlaxoSmithKline, plc (“GSK”) in 1990 July 2019 April 30, 2020, three June 30, 2020 2019, $193,000 $69,000, six June 30, 2020 2019, $193,000 $764,000, 7% The Company also generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in 2009. September 2010, 4% December 2029, six June 30, 2020 2019, $2,769,000 $2,964,000, 4% 6 $238,000 $16,000 three June 30, 2020 2019, $272,000 $1,764,000 six June 30, 2020 2019, 5% $12,000 $1,000 three June 30, 2020 2019, $152,000 $237,000 six June 30, 2020 2019, The Company's royalty revenue is seasonal, in line with the flu season, so the majority of the Company's royalty revenue is earned in the first fourth

Note 6 - Liabilities Related to

Note 6 - Liabilities Related to Sale of Future Royalties	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Liabilities Related to Sale of Future Royalties [Text Block]	NOTE 6 . Liabilities Related to Sale of Future Royalties In April 2016, $20.0 first $3.0 15% $1.0 April 1, Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the RIAA, this transaction is accounted for as a liability that is being amortized using the interest method over the life of the arrangement. The Company has no not not The following table shows the activity within the liability account during the six June 30, 2020 Total liability related to sale of future royalties, start of period $ 16,332 Non-cash royalty revenue paid to HCRP (2,800 ) Non-cash interest expense recognized 937 Total liability related to sale of future royalties, end of period 14,469 Current portion (3,150 ) Long-term portion $ 11,319

Note 7 - Leases

Note 7 - Leases	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 7 . Leas es The Company has obtained the right of use for office and manufacturing facilities under four one one three one The Company obtained the right of use of real estate located in South San Francisco, California, in June 2015 April 30, 2020, five July 2019, April 30, 2025. December 31, 2019 ( 14 February 2018, February 28, 2021, no November 30, 2018. two July 31, 2021, no September 2021. As of June 30, 2020, one 10.53% 3.55 The following table summarizes the Company's undiscounted cash payment obligations for its operating lease liabilities with initial terms of more than twelve June 30, 2020 ( Year Ending December 31, 2020 (excluding the six months ended June 30, 2020) $ 526 2021 620 2022 336 2023 348 2024 360 Thereafter 122 Undiscounted total 2,312 Less: imputed interest (388 ) Present value of future minimum payments 1,924 Current portion of operating lease liability (804 ) Operating lease liability, net of current portion $ 1,120 The Company presently has no no one Certain operating lease agreements for facilities include non-lease costs, such as common area maintenance, which are recorded as variable lease costs. Operating lease expenses for the three six June 30, 2020 2019, Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Lease cost (in thousands) (in thousands) Operating lease cost $ 212 $ 222 $ 401 $ 445 Short-term lease cost 3 4 6 7 Variable lease cost 13 40 24 88 Sublease income (55 ) (55 ) (109 ) (109 ) Total lease cost $ 173 $ 211 $ 322 $ 431 Net cash outflows associated with operating leases totaled $237,000 $240,000 three June 30, 2020 2019, $474,000 $487,000 six June 30, 2020 2019,

Note 8 - Secured Promissory Not

Note 8 - Secured Promissory Note Payable to Oxford Finance	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Secured Promissory Note Payable [Text Block]	NOTE 8 . Secured Promissory Note Payable to Oxford Finance On December 22, 2016, $5.0 $5.0 30 6.17%, four first 12 36 $325,000 The annual effective interest rate of the note, including the accretion of the final payment and the amortization of the debt discount, was approximately 10.5%. $96,000 $202,000 three six June 30, 2019, $64,000 $136,000, November 4, 2019.

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9 . Commitments and Contingencies (a) Leases The Company's lease commitments are detailed in Note 7. (b) Indemnifications In the ordinary course of business, the Company enters into agreements that may may third not may may (c) Litigation From time to time the Company may not On August 4, 2020, June 8, 2020 June 15, 2020 June 8, 2020 no no not

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 1 0 . Stock holders' Equity (a) P referred Stock The Company is authorized to issue 5,000,000 $0.0001 may, 5,000,000 one may No no (b) Common Stock At the Company's annual meeting of stockholders held on June 8, 2020, 100,000,000 150,000,000 $0.10 $0.0001. June 8, 2020, Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company's directors and all other matters requiring stockholder action. Holders of common stock are entitled to one may no June 30, 2020, no In the event of the Company's voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company's assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are no The Company had shares of common stock reserved for issuance as follows: June 30, 2020 December 31, 2019 Options issued and outstanding 6,382,232 1,811,652 PRSUs issued and outstanding 411,000 — Available for future grants of equity awards 1,620,028 295,180 Common stock warrants 1,942,654 43,370,162 Total 10,355,914 45,476,994 (c) Warrants The following warrants were outstanding as of June 30, 2020 none Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 171,667 $ 0.30 September 2024 Common Stock 241,169 $ 0.375 September 2024 Common Stock 225,966 $ 1.10 April 2024 Common Stock 163,068 $ 1.375 April 2024 Common Stock 766,584 $ 2.50 March 2025 Common Stock 280,000 $ 3.125 February 2025 Common Stock 83,286 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 1,942,654 The 280,000 March 2020 1 one $3.125 five February 27, 2020, March 2020 $453,000, $2.34 98%, 0.88%, zero 4.99 In the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Company's control, the holders of the unexercised common stock warrants exercisable for $0.30, $0.375, $1.10 $2.50 $3.125 February 2025 not

Note 11 - Equity Incentive Plan

Note 11 - Equity Incentive Plans	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 1 1 . Equity Incentive Plan s On April 23, 2019, 2019 “2019 may 2019 may 2019 not 2019 The aggregate number of shares of common stock authorized for issuance under the 2019 1,600,000 2019 June 8, 2020, 8,000,000 2019 2019 ten may In March 2020, 411,000 June 30, 2020, 411,000 June 30, 2020, $531,000 three six June 30, 2020. A summary of stock option transactions in the six June 30, 2020, Weighted Shares Number of Average Available Options Exercise For Grant Outstanding Price Balance at January 1, 2020 295,180 1,811,652 $ 2.74 2019 Plan Amendment 6,400,000 PRSUs granted, net of tax forfeitures (278,535 ) — $ — Granted (4,892,100 ) 4,892,100 $ 2.04 Exercised — (178,381 ) $ 0.65 Forfeited 85,910 (85,992 ) $ 0.39 Canceled 9,573 (57,147 ) $ 10.50 Balance at June 30, 2020 1,620,028 6,382,232 $ 2.22 As of June 30, 2020, 6,382,232 $2.22, 9.37 $43.1 1,431,750 $3.22, 8.31 $8.8 $116,000 178,381 six June 30, 2020, $524,000. No six June 30, 2019. On March 24, 2020, 2,610,000 $1.70 March 24, 2020) ( “March 25% twenty-four 24 not 2019 June 8, 2020, March On June 15, 2020, 900,000 845,280 $2.46 25% first 75% three first 50% 2019 Vesting of the performance-based options would occur if the Company achieved a specified closing price during any ten November 30, 2020, one third $5.00, one third $7.50 one third $10.00, $2.46, 105%, 0.35%, zero 5.23 $0.31 $279,000, November 30, 2020, The tranches based on closing prices of $5.00, $7.50 $10.00 July 9, 2020, July 20, 2020 July 24, 2020, $242,000 three September 30, 2020. six June 30, 2020 2019, $1.92 $0.55, Six Months Ended June 30, 2020 2019 Risk-free interest rate 0.44% 0.88% 1.89% 2.31% Expected term 5.22 - 10.00 Years 5.39 - 6.08 Years Expected volatility 94% 104% 83% 85% Dividend yield —% —% The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options and PRSUs was as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands) (in thousands) Research and development $ 1,115 $ 80 $ 1,137 $ 159 General and administrative 1,745 100 1,819 185 Total stock-based compensation $ 2,860 $ 180 $ 2,956 $ 344 As of June 30, 2020, $5.9 2.21

Note 12 - Related Party Transac

Note 12 - Related Party Transaction	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 12. In April 2020 $652,000 16 1934,

Note 13 - Net Loss Per Share

Note 13 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 1 3 . Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts): Three Months Ended June 30, Three Months Ended June 30, 2020 2019 2020 2019 Net loss $ (8,977 ) $ (5,637 ) $ (10,274 ) $ (6,976 ) Shares used to compute net loss per share – basic and diluted 74,675,131 14,597,446 67,676,138 10,969,473 Net loss per share – basic and diluted $ (0.12 ) $ (0.39 ) $ (0.15 ) $ (0.64 ) No three six June 30, 2020 2019 The following potentially dilutive securities were excluded from the computation of diluted weighted average shares outstanding because they would have been antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Options to purchase common stock 2,654,144 1,561,067 2,216,462 1,212,654 PRSUs 411,000 — 223,566 — Warrants to purchase common stock 23,522,891 11,802,695 28,729,806 5,944,948 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 26,588,035 13,363,762 31,169,834 7,157,602

Note 14 - Restructuring Costs

Note 14 - Restructuring Costs	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	NOTE 1 4 . Restructuring Costs Restructuring liabilities primarily consist of the estimated future obligations for contract suspension costs. These restructuring liabilities, all of which are expected to be paid in the year ending December 31, 2020, The Company approved a reduction-in-force during the year ended December 31, 2019, three March 31, 2020. no six June 30, 2020, 2020 not Cumulative restructuring costs incurred and a reconciliation of the change in related liabilities during the six June 30, 2020 Suspension Severance Impairment of Contract Benefits Charges Other Total (in thousands) Cumulative cost incurred as of June 30, 2020 $ 3,223 $ 368 $ 1,272 $ 160 $ 5,023 Reconciliation of liabilities: Balance at December 31, 2019 $ 3,223 $ 368 $ — $ 57 $ 3,648 Period charges — — — 103 103 Payments and settlements — (368 ) — (150 ) (518 ) Balance at June 30, 2020 $ 3,223 $ — $ — $ 10 $ 3,233

Note 15 - Subsequent Events

Note 15 - Subsequent Events	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 15 . Subsequent Events On July 13, 2020, 12,503,806 $100 July 8, 2020. $97 Since June 30, 2020, 531,013 $1.2

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation December 31, 2019, 10 March 19, 2020 ( no 2 not
Consolidation, Policy [Policy Text Block]	Basis of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk not The primary focus of the Company's investment strategy is to preserve capital and meet liquidity requirements. The Company's investment policy addresses the level of credit exposure by limiting the concentration in any one no
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification $40,000 $88,000 three six June 30, 2019, no
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company believes that the impact of accounting standards updates recently issued that are not not

Note 4 - Balance Sheet Compon_2

Note 4 - Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	June 30, 2020 December 31, 2019 (in thousands) Cash at banks $ 44,388 $ 13,511 Money market funds — 15 Total cash and cash equivalents $ 44,388 $ 13,526
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	June 30, 2020 December 31, 2019 (in thousands) Royalties receivable $ 227 $ 3,438 Customer service contracts - billed — 181 Accounts receivable $ 227 $ 3,619
Property, Plant and Equipment [Table Text Block]	June 30, 2020 December 31, 2019 (in thousands) Laboratory equipment $ 706 $ 537 Office and computer equipment 142 132 Total property and equipment 848 669 Less: accumulated depreciation (503 ) (459 ) Property and equipment, net $ 345 $ 210
Lessee, Operating Lease, Right-of-Use Assets [Table Text Block]	June 30, 2020 December 31, 2019 (in thousands) Facilities $ 1,751 $ 1,985 Office equipment 4 5 Right-of-use assets, net $ 1,755 $ 1,990
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2020 December 31, 2019 (in thousands) Purchased technology $ 22,100 $ 22,100 Intellectual property 80 80 Total cost 22,180 22,180 Less: accumulated amortization (5,953 ) (5,087 ) Intangible assets, net $ 16,227 $ 17,093
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ending December 31, Amount 2020 (six months remaining) $ 866 2021 1,732 2022 1,731 2023 1,732 2024 1,732 Thereafter 8,434 Total $ 16,227
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2020 December 31, 2019 (in thousands) Accrued compensation $ 1,009 $ 903 Accrued clinical and manufacturing expenses 4,937 3,228 Accrued professional and consulting services 49 2 Reserve for return of royalties — 178 Other liabilities, current portion 383 254 Total $ 6,378 $ 4,565

Note 6 - Liabilities Related _2

Note 6 - Liabilities Related to Sale of Future Royalties (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Total liability related to sale of future royalties, start of period $ 16,332 Non-cash royalty revenue paid to HCRP (2,800 ) Non-cash interest expense recognized 937 Total liability related to sale of future royalties, end of period 14,469 Current portion (3,150 ) Long-term portion $ 11,319

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2020 (excluding the six months ended June 30, 2020) $ 526 2021 620 2022 336 2023 348 2024 360 Thereafter 122 Undiscounted total 2,312 Less: imputed interest (388 ) Present value of future minimum payments 1,924 Current portion of operating lease liability (804 ) Operating lease liability, net of current portion $ 1,120
Lease, Cost [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Lease cost (in thousands) (in thousands) Operating lease cost $ 212 $ 222 $ 401 $ 445 Short-term lease cost 3 4 6 7 Variable lease cost 13 40 24 88 Sublease income (55 ) (55 ) (109 ) (109 ) Total lease cost $ 173 $ 211 $ 322 $ 431

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Common Stock Reserved for Issuance [Table Text Block]	June 30, 2020 December 31, 2019 Options issued and outstanding 6,382,232 1,811,652 PRSUs issued and outstanding 411,000 — Available for future grants of equity awards 1,620,028 295,180 Common stock warrants 1,942,654 43,370,162 Total 10,355,914 45,476,994
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 171,667 $ 0.30 September 2024 Common Stock 241,169 $ 0.375 September 2024 Common Stock 225,966 $ 1.10 April 2024 Common Stock 163,068 $ 1.375 April 2024 Common Stock 766,584 $ 2.50 March 2025 Common Stock 280,000 $ 3.125 February 2025 Common Stock 83,286 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 1,942,654

Note 11 - Equity Incentive Pl_2

Note 11 - Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Shares Number of Average Available Options Exercise For Grant Outstanding Price Balance at January 1, 2020 295,180 1,811,652 $ 2.74 2019 Plan Amendment 6,400,000 PRSUs granted, net of tax forfeitures (278,535 ) — $ — Granted (4,892,100 ) 4,892,100 $ 2.04 Exercised — (178,381 ) $ 0.65 Forfeited 85,910 (85,992 ) $ 0.39 Canceled 9,573 (57,147 ) $ 10.50 Balance at June 30, 2020 1,620,028 6,382,232 $ 2.22
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six Months Ended June 30, 2020 2019 Risk-free interest rate 0.44% 0.88% 1.89% 2.31% Expected term 5.22 - 10.00 Years 5.39 - 6.08 Years Expected volatility 94% 104% 83% 85% Dividend yield —% —%
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands) (in thousands) Research and development $ 1,115 $ 80 $ 1,137 $ 159 General and administrative 1,745 100 1,819 185 Total stock-based compensation $ 2,860 $ 180 $ 2,956 $ 344

Note 13 - Net Loss Per Share (T

Note 13 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Three Months Ended June 30, 2020 2019 2020 2019 Net loss $ (8,977 ) $ (5,637 ) $ (10,274 ) $ (6,976 ) Shares used to compute net loss per share – basic and diluted 74,675,131 14,597,446 67,676,138 10,969,473 Net loss per share – basic and diluted $ (0.12 ) $ (0.39 ) $ (0.15 ) $ (0.64 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Options to purchase common stock 2,654,144 1,561,067 2,216,462 1,212,654 PRSUs 411,000 — 223,566 — Warrants to purchase common stock 23,522,891 11,802,695 28,729,806 5,944,948 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 26,588,035 13,363,762 31,169,834 7,157,602

Note 14 - Restructuring Costs (

Note 14 - Restructuring Costs (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Suspension Severance Impairment of Contract Benefits Charges Other Total (in thousands) Cumulative cost incurred as of June 30, 2020 $ 3,223 $ 368 $ 1,272 $ 160 $ 5,023 Reconciliation of liabilities: Balance at December 31, 2019 $ 3,223 $ 368 $ — $ 57 $ 3,648 Period charges — — — 103 103 Payments and settlements — (368 ) — (150 ) (518 ) Balance at June 30, 2020 $ 3,223 $ — $ — $ 10 $ 3,233

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)	Mar. 02, 2020	Jun. 30, 2020	Jun. 08, 2020	Jun. 07, 2020	Dec. 31, 2019	Feb. 13, 2018
Conversion of Stock, Shares Issued (in shares)						0.22148
Proceeds from Issuance or Sale of Equity, Total	$ 10,000,000
Proceeds from Issuance or Sale of Equity, Net	9,200,000
Payments of Stock Issuance Costs	$ 775,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001	$ 0.0001	$ 0.10	$ 0.0001
Common Stock, Shares Authorized (in shares)		150,000,000	150,000,000	100,000,000	150,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001	$ 0.0001	$ 0.10	$ 0.0001
The March 2020 Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.50
Warrants and Rights Outstanding, Term (Year)	5 years
Warrants and Rights Outstanding	$ 453,000
The March 2020 Offering Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	280,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.125
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Issued During Period (in shares)	280,000
Warrants and Rights Outstanding	$ 453,000
The March 2020 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	4,000,000

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Variable Lease, Cost	$ 13,000	$ 40,000	$ 24,000	$ 88,000
Reclassification from Non-lease Cost [Member]
Variable Lease, Cost		$ 40,000		$ 88,000

Note 3 - Fair Value of Financ_2

Note 3 - Fair Value of Financial Instruments (Details Textual) - Fair Value, Recurring [Member] - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Financial Liabilities Fair Value Disclosure, Total	$ 0		$ 0
Money Market Funds [Member]
Cash and Cash Equivalents, Fair Value Disclosure		$ 15,000

Note 4 - Balance Sheet Compon_3

Note 4 - Balance Sheet Components (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Accounts Receivable, Allowance for Credit Loss, Current	$ 0		$ 0		$ 0
Depreciation, Total	25,000	$ 125,000	44,000	$ 255,000
Impairment of Property and Equipment			0	0
Amortization of Intangible Assets, Total	$ 433,000	$ 675,000	$ 866,000	$ 1,454,000
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			20 years
Finite-Lived Intangible Asset, Remaining Life (Year)			7 years 182 days
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Remaining Life (Year)			9 years 146 days
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			1 year 109 days
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			11 years 273 days

Note 4 - Balance Sheet Compon_4

Note 4 - Balance Sheet Components - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Cash at banks	$ 44,388	$ 13,511
Money market funds		15
Total cash and cash equivalents	$ 44,388	$ 13,526	$ 16,258	$ 11,506

Note 4 - Balance Sheet Compon_5

Note 4 - Balance Sheet Components - Accounts Receivable, Net of Allowance (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Accounts receivable	$ 227	$ 3,619
Royalty [Member]
Accounts receivable	227	3,438
Customer Service Contracts [Member]
Accounts receivable		$ 181

Note 4 - Balance Sheet Compon_6

Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property and equipment, gross	$ 848	$ 669
Less: accumulated depreciation	(503)	(459)
Property and equipment, net	345	210
Laboratory Equipment [Member]
Property and equipment, gross	706	537
Office Equipment [Member]
Property and equipment, gross	$ 142	$ 132

Note 4 - Balance Sheet Compon_7

Note 4 - Balance Sheet Components - Right-of-Use Assets, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Right-of-use assets, net	$ 1,755	$ 1,990
Facilities [Member]
Right-of-use assets, net	1,751	1,985
Office Equipment [Member]
Right-of-use assets, net	$ 4	$ 5

Note 4 - Balance Sheet Compon_8

Note 4 - Balance Sheet Components - Intangible assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Intangible assets, gross	$ 22,180	$ 22,180
Less: accumulated amortization	(5,953)	(5,087)
Intangible assets, net	16,227	17,093
Purchased Technology [Member]
Intangible assets, gross	22,100	22,100
Intellectual Property [Member]
Intangible assets, gross	$ 80	$ 80

Note 4 - Balance Sheet Compon_9

Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details) $ in Thousands	Jun. 30, 2020USD ($)
2020 (six months remaining)	$ 866
2021	1,732
2022	1,731
2023	1,732
2024	1,732
Thereafter	8,434
Total	$ 16,227

Note 4 - Balance Sheet Compo_10

Note 4 - Balance Sheet Components - Accrued liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Accrued compensation	$ 1,009	$ 903
Accrued clinical and manufacturing expenses	4,937	3,228
Accrued professional and consulting services	49	2
Reserve for return of royalties		178
Other liabilities, current portion	383	254
Total	$ 6,378	$ 4,565

Note 5 - Revenue 1 (Details Tex

Note 5 - Revenue 1 (Details Textual) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total	$ 0			$ 0		$ 181,000
Contract With Customer, Asset, Revenue Recognized	212,000			212,000		21,000
Contract with Customer, Liability, Total	0			0		0
Revenue, Remaining Performance Obligation, Amount	20,000			20,000		$ 211,000
Revenue from Contract with Customer, Including Assessed Tax	523,000	$ 85,000		3,425,000	$ 5,492,000
Income Tax Expense (Benefit), Total	26,000	13,000		$ 179,000	263,000
Foreign Tax Authority [Member] | National Tax Agency, Japan [Member]
Royalty Withholding Tax				5.00%
Income Tax Expense (Benefit), Total	12,000	1,000		$ 152,000	237,000
Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax	193,000	69,000		2,962,000	3,728,000
Royalty [Member] | GSK Research and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax	193,000	69,000		193,000	764,000
Royalty Percentage			7.00%
Royalty [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax				$ 2,769,000	2,964,000
Royalty Percentage				4.00%		4.00%
Non-cash Royalty Revenue, Related to Sale of Future Royalties	$ 238,000	$ 16,000		$ 272,000	$ 1,764,000

Note 5 - Revenue 2 (Details Tex

Note 5 - Revenue 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01	Jun. 30, 2020
Revenue, Remaining Performance Obligation, Percentage	100.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	90 days

Note 6 - Liabilities Related _3

Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual) - HCRP [Member] $ in Millions	1 Months Ended
	Apr. 30, 2016USD ($)
Proceeds from Sale of Future Royalties, Net	$ 20
Royalty Interest Due Each Year	$ 3
Royalty Interest, Percentage of Additional Royalties Due Each Year	15.00%
Royalty Interest, Additional Royalties Due Each Year	$ 1

Note 6 - Liabilities Related _4

Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Current portion	$ (3,150)	$ (2,916)
Long-term portion	11,319	$ 13,416
HealthCare Royalty Partners III, L.P. [Member] | Royalty Arrangement [Member]
Total liability related to sale of future royalties, start of period	16,332
Non-cash royalty revenue paid to HCRP	(2,800)
Non-cash interest expense recognized	937
Total liability related to sale of future royalties, end of period	14,469
Current portion	(3,150)
Long-term portion	$ 11,319

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Lessee, Operating Lease, Number of Right-of-Use Leases	4		4
Lessee, Operating Lease, Number of Right-of-Use Leases, Terminated	1		1
Lessee, Operating Lease, Number of Right-of-Use Leases, Subleased	1		1
Lessee, Operating Lease, Number Leases Exceeding One Year	3		3
Lessee, Operating Lease, Renewal Term (Year)	5 years		5 years
Operating Lease, Weighted Average Discount Rate, Percent	10.53%		10.53%
Operating Lease, Weighted Average Remaining Lease Term (Year)	3 years 200 days		3 years 200 days
Lessee, Finance Lease, Number of Leases	0		0
Short-term Lease Commitment, Amount	$ 0		$ 0
Operating Lease, Payments	$ 237,000	$ 240,000	$ 474,000	$ 487,000

Note 7 - Leases - Lease Liabili

Note 7 - Leases - Lease Liabilities Payment Obligations (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
2020 (excluding the six months ended June 30, 2020)	$ 526
2021	620
2022	336
2023	348
2024	360
Thereafter	122
Undiscounted total	2,312
Less: imputed interest	(388)
Present value of future minimum payments	1,924
Current portion of operating lease liability	(804)	$ (841)
Operating lease liability, net of current portion	$ 1,120	$ 1,472

Note 7 - Leases - Operating Lea

Note 7 - Leases - Operating Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating lease cost	$ 212	$ 222	$ 401	$ 445
Short-term lease cost	3	4	6	7
Variable lease cost	13	40	24	88
Sublease income	(55)	(55)	(109)	(109)
Total lease cost	$ 173	$ 211	$ 322	$ 431

Note 8 - Secured Promissory N_2

Note 8 - Secured Promissory Note Payable to Oxford Finance (Details Textual) - Loan Agreement [Member] - Oxford Finance [Member] - USD ($)	Dec. 22, 2016	Jun. 30, 2019	Jun. 30, 2019
Long-term Debt, Gross	$ 5,000,000
Debt Instrument, Term (Year)	4 years
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid	$ 325,000
Debt Instrument, Interest Rate, Effective Percentage	10.50%
Interest Expense, Debt, Total		$ 96,000	$ 202,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total		$ 64,000	$ 136,000
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	6.17%

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual)	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 08, 2020$ / sharesshares	Jun. 07, 2020$ / sharesshares	Mar. 02, 2020USD ($)yr$ / sharesshares	Dec. 31, 2019$ / sharesshares
Preferred Stock, Shares Authorized (in shares) | shares	5,000,000				5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.10		$ 0.0001
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares	0				0
Common Stock, Shares Authorized (in shares) | shares	150,000,000	150,000,000	100,000,000		150,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.10		$ 0.0001
Dividends, Total | $	$ 0
The March 2020 Offering Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				280,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 3.125
Warrants and Rights Outstanding, Term (Year)				5 years
Warrants and Rights Outstanding | $				$ 453,000
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input				2.34
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input				0.98
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0.0088
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr				4.99
First Set of Warrants Expiring September 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.30
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)	0.30
Second Set of Warrants Expiring April 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	1.375
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)	0.375
First Set of Warrants Expiring April 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	1.10
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)	1.10
Warrants Expiring March 2025 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	2.50
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)	2.50
Warrants Expiring March 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	3.125
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)	$ 3.125

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) - shares	Jun. 30, 2020	Dec. 31, 2019
Common stock reserved for issuance (in shares)	10,355,914	45,476,994
Options Issued and Outstanding [Member]
Common stock reserved for issuance (in shares)	6,382,232	1,811,652
Performance-based Restricted Stock Units (PRSUs) [Member]
Common stock reserved for issuance (in shares)	411,000
Options Available for Future Grants [Member]
Common stock reserved for issuance (in shares)	1,620,028	295,180
Common Warrants [Member]
Common stock reserved for issuance (in shares)	1,942,654	43,370,162

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity - Summary of Warrants Outstanding (Details)	Jun. 30, 2020$ / sharesshares
Warrants outstanding (in shares)	1,942,654
First Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	171,667
Exercise Price (in dollars per share) | $ / shares	$ 0.30
Second Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	241,169
Exercise Price (in dollars per share) | $ / shares	$ 0.375
First Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	225,966
Exercise Price (in dollars per share) | $ / shares	$ 1.10
Second Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	163,068
Exercise Price (in dollars per share) | $ / shares	$ 1.375
Warrants Expiring March 2025 [Member]
Warrants outstanding (in shares)	766,584
Exercise Price (in dollars per share) | $ / shares	$ 2.50
Warrants Expiring February 2025 [Member]
Warrants outstanding (in shares)	280,000
Exercise Price (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring March 2024 [Member]
Warrants outstanding (in shares)	83,286
Exercise Price (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring December 2026 [Member]
Warrants outstanding (in shares)	10,914
Exercise Price (in dollars per share) | $ / shares	$ 22.99

Note 11 - Equity Incentive Pl_3

Note 11 - Equity Incentive Plans (Details Textual) - USD ($)	Jul. 24, 2020	Jul. 20, 2020	Jul. 09, 2020	Jun. 23, 2020	Jun. 15, 2020	Mar. 24, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Apr. 23, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						2,610,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)							6,382,232		6,382,232		6,382,232		1,811,652
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)							$ 2.22		$ 2.22		$ 2.22		$ 2.74
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)											9 years 135 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value							$ 43,100,000		$ 43,100,000		$ 43,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)							1,431,750		1,431,750		1,431,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)							$ 3.22		$ 3.22		$ 3.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)											8 years 113 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value							$ 8,800,000		$ 8,800,000		$ 8,800,000
Proceeds from Stock Options Exercised											$ 116,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)											178,381	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value											$ 524,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)						$ 1.70					$ 2.04
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount							$ 5,900,000		$ 5,900,000		$ 5,900,000
Performance-based Restricted Stock Units (PRSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)								411,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)							411,000		411,000		411,000
Share-based Payment Arrangement, Expense									$ 531,000		$ 531,000
March Option Awards [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						25.00%
March Option Awards [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)						2 years
Performance-based Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					900,000
Time-based Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					845,280
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 2.46
Time-based Options [Member] | Share-based Payment Arrangement, Tranche One [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					25.00%
Time-based Options [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					75.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)					3 years
Time-based Options [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Accelerated Vesting Percentage					50.00%
Performance-based Options and Time-based Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 2.46
Market Based Options [Member] | Chief Executive Officer [Member]
Share Price (in dollars per share)							$ 2.46		$ 2.46		$ 2.46
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							105.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							0.35%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)							5 years 83 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)							$ 0.31
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Fair Value							$ 279,000
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount							$ 242,000		$ 242,000		$ 242,000
Market Based Options [Member] | Share-based Payment Arrangement, Tranche One [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)					$ 5
Market Based Options [Member] | Share-based Payment Arrangement, Tranche One [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)			$ 5
Market Based Options [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)					$ 7.50
Market Based Options [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)		$ 7.50
Market Based Options [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)					$ 10
Market Based Options [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)	$ 10
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense									$ 2,860,000	$ 180,000	$ 2,956,000	$ 344,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate											0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)											$ 1.92	$ 0.55
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)											2 years 76 days
The 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				8,000,000										1,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)				10 years

Note 11 - Equity Incentive Pl_4

Note 11 - Equity Incentive Plans - Summary of Stock Option Transactions (Details) - $ / shares	Mar. 24, 2020	Jun. 30, 2020	Jun. 30, 2019
Shares available for grant, balance (in shares)		295,180
Number of options outstanding, beginning balance (in shares)		1,811,652
Weighted average exercise price, balance (in dollars per share)		$ 2.74
Shares availabe for grant, 2019 Plan Amendment (in shares)		6,400,000
Shares available for grant, granted (in shares)		(4,892,100)
Number of options outstanding, granted (in shares)		4,892,100
Weighted average exercise price, granted (in dollars per share)	$ 1.70	$ 2.04
Number of options outstanding, exercised (in shares)		(178,381)	0
Weighted average exercise price, exercised (in dollars per share)		$ 0.65
Shares available for grant, forfeited (in shares)		85,910
Number of options outstanding, forfeited (in shares)		(85,992)
Weighted average exercise price, forfeited (in dollars per share)		$ 0.39
Shares available for grant, canceled (in shares)		9,573
Number of options outstanding, canceled (in shares)		(57,147)
Weighted average exercise price, canceled (in dollars per share)		$ 10.50
Shares available for grant, balance (in shares)		1,620,028
Number of options outstanding, balance (in shares)		6,382,232
Weighted average exercise price, balance (in dollars per share)		$ 2.22
Performance-based Restricted Stock Units (PRSUs) [Member]
Shares available for grant, PRSU's granted (in shares)		(278,535)

Note 11 - Equity Incentive Pl_5

Note 11 - Equity Incentive Plans - Assumptions of Options (Details) - Share-based Payment Arrangement, Option [Member]	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Dividend yield	0.00%	0.00%
Minimum [Member]
Risk-free interest rate	0.44%	1.89%
Expected term (Year)	5 years 80 days	5 years 142 days
Expected volatility	94.00%	83.00%
Maximum [Member]
Risk-free interest rate	0.88%	2.31%
Expected term (Year)	10 years	6 years 29 days
Expected volatility	104.00%	85.00%

Note 11 - Equity Incentive Pl_6

Note 11 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) - Share-based Payment Arrangement, Option [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Expense	$ 2,860	$ 180	$ 2,956	$ 344
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense	1,115	80	1,137	159
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense	$ 1,745	$ 100	$ 1,819	$ 185

Note 12 - Related Party Trans_2

Note 12 - Related Party Transaction (Details Textual)	1 Months Ended
	Apr. 30, 2020USD ($)
Disgorgement of Stockholder Short-swing Profits [Member]
Related Party Transaction, Amounts of Transaction	$ 652,000

Note 13 - Net Loss Per Share (D

Note 13 - Net Loss Per Share (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Dilutive Securities, Effect on Basic Earnings Per Share, Total	$ 0	$ 0	$ 0	$ 0

Note 13 - Net Loss Per Share At

Note 13 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Net loss	$ (8,977)	$ (5,637)	$ (10,274)	$ (6,976)
Shares used to compute net loss per share - basic and diluted (in shares)	74,675,131	14,597,446	67,676,138	10,969,473
Net loss per share - basic and diluted (in dollars per share)	$ (0.12)	$ (0.39)	$ (0.15)	$ (0.64)

Note 13 - Net Loss Per Share _2

Note 13 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	26,588,035	13,363,762	31,169,834	7,157,602
Share-based Payment Arrangement, Option [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	2,654,144	1,561,067	2,216,462	1,212,654
Performance-based Restricted Stock Units (PRSUs) [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	411,000		223,566
Warrant [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	23,522,891	11,802,695	28,729,806	5,944,948

Note 14 - Restructuring Costs -

Note 14 - Restructuring Costs - Restructuring Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Cumulative cost incurred	$ 5,023		$ 5,023
Balance			3,648
Restructuring costs	39		103
Payments and settlements			(518)
Balance	3,233		3,233
Contract Termination [Member]
Cumulative cost incurred	3,223		3,223
Balance			3,223
Restructuring costs
Payments and settlements
Balance	3,223		3,223
Employee Severance [Member]
Cumulative cost incurred	368		368
Balance			368
Restructuring costs
Payments and settlements			(368)
Balance
Impairment Charges [Member]
Cumulative cost incurred	1,272		1,272
Balance
Restructuring costs
Payments and settlements
Balance
Other Restructuring [Member]
Cumulative cost incurred	160		160
Balance			57
Restructuring costs			103
Payments and settlements			(150)
Balance	$ 10		$ 10

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	Jul. 13, 2020	Aug. 10, 2020	Jun. 30, 2020	Jun. 30, 2019
Stock Issued During Period, Value, New Issues				$ 2,440
Proceeds from Issuance of Common Stock			$ 9,175	2,540
Proceeds from Warrant Exercises			$ 24,658
Subsequent Event [Member]
Stock Issued During Period, Value, Exercise of Common Stock Warrants (in shares)		531,013
Proceeds from Warrant Exercises		$ 1,200
Subsequent Event [Member] | ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)	12,503,806
Stock Issued During Period, Value, New Issues	$ 100,000
Proceeds from Issuance of Common Stock	$ 97,000